IL-17

We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents –…

The ACR Convergence 2024 meeting provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics…

At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A…